Sionna Therapeutics’ (SION) Market Outperform Rating Reiterated at Citizens Jmp

Sionna Therapeutics (NASDAQ:SION)‘s stock had its “market outperform” rating restated by Citizens Jmp in a research report issued on Tuesday,Benzinga reports. They currently have a $63.00 price target on the stock. Citizens Jmp’s price objective suggests a potential upside of 50.21% from the company’s previous close.

SION has been the subject of a number of other research reports. Lifesci Capital upgraded shares of Sionna Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 25th. Guggenheim boosted their price target on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Stifel Nicolaus increased their price objective on shares of Sionna Therapeutics from $44.00 to $55.00 and gave the company a “buy” rating in a report on Monday, May 18th. Wedbush started coverage on Sionna Therapeutics in a research report on Tuesday, May 5th. They set an “outperform” rating and a $53.00 price objective for the company. Finally, JonesTrading lifted their target price on Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Three research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $53.22.

Sionna Therapeutics Trading Up 2.0%

NASDAQ SION opened at $41.94 on Tuesday. Sionna Therapeutics has a 12 month low of $12.52 and a 12 month high of $48.44. The stock has a market cap of $1.89 billion, a PE ratio of -21.73 and a beta of 1.35. The stock’s 50 day moving average is $39.78 and its 200 day moving average is $39.66.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). On average, analysts forecast that Sionna Therapeutics will post -2.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Orbimed Advisors Llc sold 235,863 shares of the business’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total value of $10,528,924.32. Following the sale, the director directly owned 3,247,025 shares in the company, valued at $144,947,196. The trade was a 6.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 235,863 shares of the company’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the sale, the director owned 3,247,025 shares in the company, valued at $144,947,196. This represents a 6.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 1,717,760 shares of company stock valued at $77,562,902. 3.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Sionna Therapeutics

Several large investors have recently added to or reduced their stakes in SION. Russell Investments Group Ltd. bought a new stake in shares of Sionna Therapeutics in the 3rd quarter valued at approximately $30,000. BNP Paribas Financial Markets bought a new position in shares of Sionna Therapeutics during the 2nd quarter valued at approximately $31,000. GF Fund Management CO. LTD. bought a new position in shares of Sionna Therapeutics during the 4th quarter valued at approximately $36,000. Balyasny Asset Management L.P. purchased a new stake in Sionna Therapeutics during the 4th quarter valued at $58,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Sionna Therapeutics during the 4th quarter valued at $89,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.